(NASDAQ: AMPH) Amphastar Pharmaceuticals's forecast annual revenue growth rate of 5.23% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.82%.
Amphastar Pharmaceuticals's revenue in 2026 is $719,887,000.On average, 9 Wall Street analysts forecast AMPH's revenue for 2026 to be $35,009,892,452, with the lowest AMPH revenue forecast at $32,578,051,287, and the highest AMPH revenue forecast at $36,834,227,028. On average, 9 Wall Street analysts forecast AMPH's revenue for 2027 to be $36,677,246,236, with the lowest AMPH revenue forecast at $34,014,017,199, and the highest AMPH revenue forecast at $39,025,606,287.
In 2028, AMPH is forecast to generate $37,982,999,758 in revenue, with the lowest revenue forecast at $33,169,224,615 and the highest revenue forecast at $40,731,071,015.